Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines

S. L. Rybalko; M. L. Khristova; A. V. Shapiro; L. D. Varbanets; N. L. Zubkova; V. I. Zadorozhna; N. V. Ivans'ka; I. B. Sorokulova; T. F. Grytsak; T. M. Furzikova; I. I. Pinchuk; V. Patskovski Yu; S. T. Diadiun; V. V. Smirnov; M. A. Urdaci

doi:10.7124/bc.00065A

Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines

S. L. Rybalko, M. L. Khristova, A. V. Shapiro, L. D. Varbanets, N. L. Zubkova, V. I. Zadorozhna, N. V. Ivans'ka, I. B. Sorokulova, T. F. Grytsak, T. M. Furzikova, I. I. Pinchuk, V. Patskovski Yu, S. T. Diadiun, V. V. Smirnov, M. A. Urdaci

Research output: Contribution to journal › Article › peer-review

2 Scopus citations

Abstract

The authors have compared activities of three bacterial adjuvant-neuraminins isolated from culture fluids of Staphylococcus aureus, Streptococcus pneumoniae and Bacillus subtilis 105 taking into consideration their influence on the immune response following anti-influenza and anti-poliomyelitis vaccination. Bacterial adjuvants stimulate humoral immune response and help to develop more early anti-influenza IgG together with IgM antibodies (on the first week of immunization). This phenomenon may be due to the peptide mimicry of neuraminins and influenza virus hemagglutinins. In an animal model the S. aureus neuraminin is shown to stimulate a more prolonged antibody synthesis against polioviruses types 1 and 3. Due to such mimicry, neuraminins may be used for priming and acceleration of prolonged immune answer following booster immunization. Being non-toxic, neuraminins are promising compounds for the adjuvant therapy.

Original language	English (US)
Pages (from-to)	262-269
Number of pages	8
Journal	Biopolymers and Cell
Volume	19
Issue number	3
DOIs	https://doi.org/10.7124/bc.00065A
State	Published - 2003

All Science Journal Classification (ASJC) codes

General Biochemistry, Genetics and Molecular Biology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.7124/bc.00065A

Cite this

Rybalko, S. L., Khristova, M. L., Shapiro, A. V., Varbanets, L. D., Zubkova, N. L., Zadorozhna, V. I., Ivans'ka, N. V., Sorokulova, I. B., Grytsak, T. F., Furzikova, T. M., Pinchuk, I. I., Patskovski Yu, V., Diadiun, S. T., Smirnov, V. V., & Urdaci, M. A. (2003). Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines. Biopolymers and Cell, 19(3), 262-269. https://doi.org/10.7124/bc.00065A

@article{fd3cab6e7ce8417a82770edff4cc90f7,

title = "Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines",

abstract = "The authors have compared activities of three bacterial adjuvant-neuraminins isolated from culture fluids of Staphylococcus aureus, Streptococcus pneumoniae and Bacillus subtilis 105 taking into consideration their influence on the immune response following anti-influenza and anti-poliomyelitis vaccination. Bacterial adjuvants stimulate humoral immune response and help to develop more early anti-influenza IgG together with IgM antibodies (on the first week of immunization). This phenomenon may be due to the peptide mimicry of neuraminins and influenza virus hemagglutinins. In an animal model the S. aureus neuraminin is shown to stimulate a more prolonged antibody synthesis against polioviruses types 1 and 3. Due to such mimicry, neuraminins may be used for priming and acceleration of prolonged immune answer following booster immunization. Being non-toxic, neuraminins are promising compounds for the adjuvant therapy.",

author = "Rybalko, {S. L.} and Khristova, {M. L.} and Shapiro, {A. V.} and Varbanets, {L. D.} and Zubkova, {N. L.} and Zadorozhna, {V. I.} and Ivans'ka, {N. V.} and Sorokulova, {I. B.} and Grytsak, {T. F.} and Furzikova, {T. M.} and Pinchuk, {I. I.} and {Patskovski Yu}, V. and Diadiun, {S. T.} and Smirnov, {V. V.} and Urdaci, {M. A.}",

year = "2003",

doi = "10.7124/bc.00065A",

language = "English (US)",

volume = "19",

pages = "262--269",

journal = "Biopolymers and Cell",

issn = "0233-7657",

publisher = "National Academy of Sciences of Ukraine",

number = "3",

}

Rybalko, SL, Khristova, ML, Shapiro, AV, Varbanets, LD, Zubkova, NL, Zadorozhna, VI, Ivans'ka, NV, Sorokulova, IB, Grytsak, TF, Furzikova, TM, Pinchuk, II, Patskovski Yu, V, Diadiun, ST, Smirnov, VV & Urdaci, MA 2003, 'Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines', Biopolymers and Cell, vol. 19, no. 3, pp. 262-269. https://doi.org/10.7124/bc.00065A

TY - JOUR

T1 - Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines

AU - Rybalko, S. L.

AU - Khristova, M. L.

AU - Shapiro, A. V.

AU - Varbanets, L. D.

AU - Zubkova, N. L.

AU - Zadorozhna, V. I.

AU - Ivans'ka, N. V.

AU - Sorokulova, I. B.

AU - Grytsak, T. F.

AU - Furzikova, T. M.

AU - Pinchuk, I. I.

AU - Patskovski Yu, V.

AU - Diadiun, S. T.

AU - Smirnov, V. V.

AU - Urdaci, M. A.

PY - 2003

Y1 - 2003

N2 - The authors have compared activities of three bacterial adjuvant-neuraminins isolated from culture fluids of Staphylococcus aureus, Streptococcus pneumoniae and Bacillus subtilis 105 taking into consideration their influence on the immune response following anti-influenza and anti-poliomyelitis vaccination. Bacterial adjuvants stimulate humoral immune response and help to develop more early anti-influenza IgG together with IgM antibodies (on the first week of immunization). This phenomenon may be due to the peptide mimicry of neuraminins and influenza virus hemagglutinins. In an animal model the S. aureus neuraminin is shown to stimulate a more prolonged antibody synthesis against polioviruses types 1 and 3. Due to such mimicry, neuraminins may be used for priming and acceleration of prolonged immune answer following booster immunization. Being non-toxic, neuraminins are promising compounds for the adjuvant therapy.

AB - The authors have compared activities of three bacterial adjuvant-neuraminins isolated from culture fluids of Staphylococcus aureus, Streptococcus pneumoniae and Bacillus subtilis 105 taking into consideration their influence on the immune response following anti-influenza and anti-poliomyelitis vaccination. Bacterial adjuvants stimulate humoral immune response and help to develop more early anti-influenza IgG together with IgM antibodies (on the first week of immunization). This phenomenon may be due to the peptide mimicry of neuraminins and influenza virus hemagglutinins. In an animal model the S. aureus neuraminin is shown to stimulate a more prolonged antibody synthesis against polioviruses types 1 and 3. Due to such mimicry, neuraminins may be used for priming and acceleration of prolonged immune answer following booster immunization. Being non-toxic, neuraminins are promising compounds for the adjuvant therapy.

UR - http://www.scopus.com/inward/record.url?scp=84890808011&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84890808011&partnerID=8YFLogxK

U2 - 10.7124/bc.00065A

DO - 10.7124/bc.00065A

M3 - Article

AN - SCOPUS:84890808011

SN - 0233-7657

VL - 19

SP - 262

EP - 269

JO - Biopolymers and Cell

JF - Biopolymers and Cell

IS - 3

ER -

Usage of new bacterial adjuvants for vaccination by anti-influenza and anti-poliomyelitis vaccines

Abstract

All Science Journal Classification (ASJC) codes

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this